$ALT
Altimmune Inc

2023 Q4 Form 10-Q Financial Statement

#000132619023000047 Filed on November 07, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $37.00K $362.0K
YoY Change -154.41% 18000.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.332M $4.510M
YoY Change -74.72% 0.4%
% of Gross Profit
Research & Development $16.91M $18.39M
YoY Change -76.03% -9.25%
% of Gross Profit
Depreciation & Amortization $477.0K
YoY Change
% of Gross Profit
Operating Expenses $21.24M $22.90M
YoY Change -75.77% -7.48%
Operating Profit -$22.54M
YoY Change -8.94%
Interest Expense $1.962M $29.00K
YoY Change -31.45% -54.69%
% of Operating Profit
Other Income/Expense, Net $20.00K $1.869M
YoY Change -162.5% 79.88%
Pretax Income -$31.64M -$20.67M
YoY Change -62.74% -12.83%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$31.64M -$20.67M
YoY Change -62.65% -12.1%
Net Earnings / Revenue -85516.22% -5710.22%
Basic Earnings Per Share -$0.39
Diluted Earnings Per Share -$0.54 -$0.39
COMMON SHARES
Basic Shares Outstanding 53.73M 52.69M
Diluted Shares Outstanding 53.63M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $197.8M $140.8M
YoY Change 7.0% -30.24%
Cash & Equivalents $135.1M $86.86M
Short-Term Investments $62.70M $53.90M
Other Short-Term Assets $6.958M $7.600M
YoY Change 29.04% 57.55%
Inventory
Prepaid Expenses
Receivables $1.111M $900.0K
Other Receivables $3.742M $3.600M
Total Short-Term Assets $209.6M $153.0M
YoY Change 8.72% -27.51%
LONG-TERM ASSETS
Property, Plant & Equipment $1.014M $765.0K
YoY Change -6.2% -34.73%
Goodwill
YoY Change
Intangibles $0.00
YoY Change -100.0%
Long-Term Investments
YoY Change
Other Assets $363.0K $425.0K
YoY Change -40.98% -37.68%
Total Long-Term Assets $1.014M $13.61M
YoY Change -92.82% -4.65%
TOTAL ASSETS
Total Short-Term Assets $209.6M $153.0M
Total Long-Term Assets $1.014M $13.61M
Total Assets $210.6M $166.6M
YoY Change 1.79% -26.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.070M $3.046M
YoY Change -56.91% 114.66%
Accrued Expenses $10.07M $8.800M
YoY Change -9.1% -33.1%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $12.14M $11.87M
YoY Change -28.8% -24.59%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $4.305M
YoY Change -100.0% -4.46%
Other Long-Term Liabilities $4.398M $46.00K
YoY Change 7230.0% -30.3%
Total Long-Term Liabilities $4.398M $4.351M
YoY Change -5.24% -4.83%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.14M $11.87M
Total Long-Term Liabilities $4.398M $4.351M
Total Liabilities $16.54M $16.18M
YoY Change -23.55% -20.11%
SHAREHOLDERS EQUITY
Retained Earnings -$466.3M -$434.7M
YoY Change 23.41% 22.03%
Common Stock $7.000K $5.000K
YoY Change 40.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $194.1M $150.4M
YoY Change
Total Liabilities & Shareholders Equity $210.6M $166.6M
YoY Change 1.79% -26.06%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$31.64M -$20.67M
YoY Change -62.65% -12.1%
Depreciation, Depletion And Amortization $477.0K
YoY Change
Cash From Operating Activities -$16.53M -$20.49M
YoY Change -4.48% 36.15%
INVESTING ACTIVITIES
Capital Expenditures -$3.000K $0.00
YoY Change -107.89% -100.0%
Acquisitions
YoY Change
Other Investing Activities -$7.961M $4.400M
YoY Change -881.26% -117.36%
Cash From Investing Activities -$7.958M $4.400M
YoY Change -911.21% -117.32%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 72.76M 590.0K
YoY Change -169297.67% -98.16%
NET CHANGE
Cash From Operating Activities -16.53M -20.49M
Cash From Investing Activities -7.958M 4.400M
Cash From Financing Activities 72.76M 590.0K
Net Change In Cash 48.27M -15.50M
YoY Change -394.89% 84.68%
FREE CASH FLOW
Cash From Operating Activities -$16.53M -$20.49M
Capital Expenditures -$3.000K $0.00
Free Cash Flow -$16.53M -$20.49M
YoY Change -4.71% 36.69%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.39
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.10
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.37
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53633354
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49286535
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51495957
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
45881547
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52858920
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49199845
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001326190
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52858920
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-32587
dei Entity Registrant Name
EntityRegistrantName
ALTIMMUNE, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-2726770
dei Entity Address Address Line1
EntityAddressAddressLine1
910 Clopper Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 201S
dei Entity Address City Or Town
EntityAddressCityOrTown
Gaithersburg
dei Entity Address State Or Province
EntityAddressStateOrProvince
MD
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20878
dei City Area Code
CityAreaCode
240
dei Local Phone Number
LocalPhoneNumber
654-1450
dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
ALT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
53728871
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
86855000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
111097000
CY2023Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
41000
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
34000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
86896000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
111131000
CY2023Q3 us-gaap Short Term Investments
ShortTermInvestments
53924000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
73783000
CY2023Q3 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
876000
CY2022Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
173000
CY2023Q3 alt Income Taxes And Research Development Incentive Receivable Current
IncomeTaxesAndResearchDevelopmentIncentiveReceivableCurrent
3653000
CY2022Q4 alt Income Taxes And Research Development Incentive Receivable Current
IncomeTaxesAndResearchDevelopmentIncentiveReceivableCurrent
2368000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7615000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5358000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
152964000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
192813000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
765000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1081000
CY2023Q3 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
12419000
CY2022Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
12419000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
425000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
615000
CY2023Q3 us-gaap Assets
Assets
166573000
CY2022Q4 us-gaap Assets
Assets
206928000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3046000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4804000
CY2023Q3 alt Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
8825000
CY2022Q4 alt Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
12250000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
11871000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17054000
CY2023Q3 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
4305000
CY2022Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
4581000
CY2023Q3 us-gaap Liabilities
Liabilities
16176000
CY2022Q4 us-gaap Liabilities
Liabilities
21635000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52858920
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49199845
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
5000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
590206000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
568399000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-434690000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-377884000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5124000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5227000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
150397000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
185293000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
166573000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
206928000
CY2023Q3 us-gaap Revenues
Revenues
362000
CY2022Q3 us-gaap Revenues
Revenues
2000
us-gaap Revenues
Revenues
389000
us-gaap Revenues
Revenues
42000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18388000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20262000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
48890000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
51359000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4514000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4492000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13805000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13329000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
22902000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
24754000
us-gaap Operating Expenses
OperatingExpenses
62695000
us-gaap Operating Expenses
OperatingExpenses
64688000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-22540000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-24752000
us-gaap Operating Income Loss
OperatingIncomeLoss
-62306000
us-gaap Operating Income Loss
OperatingIncomeLoss
-64646000
CY2023Q3 us-gaap Interest Expense
InterestExpense
29000
CY2022Q3 us-gaap Interest Expense
InterestExpense
64000
us-gaap Interest Expense
InterestExpense
33000
us-gaap Interest Expense
InterestExpense
191000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1884000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1053000
us-gaap Investment Income Interest
InvestmentIncomeInterest
5387000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1402000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
14000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
50000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
146000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
185000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1869000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1039000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5500000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1396000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-20671000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-23713000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-56806000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-63250000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-197000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-197000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-20671000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-23516000
us-gaap Net Income Loss
NetIncomeLoss
-56806000
us-gaap Net Income Loss
NetIncomeLoss
-63053000
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
56000
CY2022Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-143000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
103000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-263000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-20615000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-23659000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-56703000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-63316000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.39
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.10
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.37
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53633354
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49286535
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51495957
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45881547
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
185293000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2675000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
61000
CY2023Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-484000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
135000
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
126000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-20074000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
167732000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2786000
CY2023Q2 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-16000
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
13352000
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-79000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-16061000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
167714000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2710000
CY2023Q3 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-2000
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
510000
CY2023Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
80000
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
56000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-20671000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
150397000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
199135000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2033000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
197000
CY2022Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-170000
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
113000
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2990000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-19430000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
184868000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2048000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
403000
CY2022Q2 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-80000
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
21347000
CY2022Q2 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
6176000
CY2022Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-120000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-20107000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
194535000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2128000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
268000
CY2022Q3 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-140000
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
31829000
CY2022Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
68000
CY2022Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-143000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-23516000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
205029000
us-gaap Profit Loss
ProfitLoss
-56806000
us-gaap Profit Loss
ProfitLoss
-63053000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
86000
us-gaap Share Based Compensation
ShareBasedCompensation
8171000
us-gaap Share Based Compensation
ShareBasedCompensation
6209000
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
-1413000
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
31000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
134000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
183000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
704000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
204000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2043000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3204000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1758000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-615000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-3306000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
7555000
alt Increase Decrease In Income Taxes And Tax Incentive Receivable
IncreaseDecreaseInIncomeTaxesAndTaxIncentiveReceivable
1284000
alt Increase Decrease In Income Taxes And Tax Incentive Receivable
IncreaseDecreaseInIncomeTaxesAndTaxIncentiveReceivable
-1690000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-59277000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-45280000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
76544000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
54806000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
74292000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
47000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
88000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
21691000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-74380000
alt Payments Of Deferred Offering Costs
PaymentsOfDeferredOfferingCosts
195000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13862000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
56166000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
215000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
181000
alt Payments Of Conditional Economic Incentive
PaymentsOfConditionalEconomicIncentive
90000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
61000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
868000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
502000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
391000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
13351000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
56824000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-24235000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-62836000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
111131000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
190335000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
86896000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
127499000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
6176000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The preparation of these financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include, but are not </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">limited to, the valuation of share-based awards, income taxes, and accruals for research and development activities. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable. However, actual results could differ from those estimates and there may be changes to the Company’s estimates in future periods.</p>
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-200000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-200000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
73783000
CY2023Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
54008000
CY2023Q3 us-gaap Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax
-84000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
53924000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
73970000
CY2022Q4 us-gaap Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax
-187000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
73783000
CY2023Q3 alt Assets Or Liabilities Measured At Fair Value On Non Recurring Basis
AssetsOrLiabilitiesMeasuredAtFairValueOnNonRecurringBasis
0
CY2022Q4 alt Assets Or Liabilities Measured At Fair Value On Non Recurring Basis
AssetsOrLiabilitiesMeasuredAtFairValueOnNonRecurringBasis
0
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
us-gaap Operating Lease Expense
OperatingLeaseExpense
400000
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
us-gaap Operating Lease Expense
OperatingLeaseExpense
400000
us-gaap Operating Lease Payments
OperatingLeasePayments
400000
us-gaap Operating Lease Payments
OperatingLeasePayments
400000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
788000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1124000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
424000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
596000
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y7M6D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y3M18D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.072
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.072
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52858920
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
4581000
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
313000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
276000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2427000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2955000
CY2023Q3 alt Accrued Research And Development
AccruedResearchAndDevelopment
5537000
CY2022Q4 alt Accrued Research And Development
AccruedResearchAndDevelopment
7295000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
485000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
452000
CY2022Q4 alt Excess Tax Refund Payable
ExcessTaxRefundPayable
1169000
CY2023Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
63000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
103000
CY2023Q3 alt Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
8825000
CY2022Q4 alt Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
12250000
CY2023Q3 alt Research And Development Incentive Credit
ResearchAndDevelopmentIncentiveCredit
3796000
CY2022Q4 alt Research And Development Incentive Credit
ResearchAndDevelopmentIncentiveCredit
3599000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
303000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
672000
CY2023Q3 alt Economic Conditional Incentive Grants
EconomicConditionalIncentiveGrants
160000
CY2022Q4 alt Economic Conditional Incentive Grants
EconomicConditionalIncentiveGrants
250000
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
46000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
60000
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
4305000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1015166
CY2023Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.66
alt Class Of Warrant Or Right Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm
P0Y2M12D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5079329
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.31
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y10M24D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
239000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2260984
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.81
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y9M18D
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
200000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4769311
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
9.28
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P5Y10M24D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
235000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2710000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2128000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8171000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6209000

Files In Submission

Name View Source Status
0001326190-23-000047-index-headers.html Edgar Link pending
0001326190-23-000047-index.html Edgar Link pending
0001326190-23-000047.txt Edgar Link pending
0001326190-23-000047-xbrl.zip Edgar Link pending
alt-20230930.xsd Edgar Link pending
alt-20230930x10q.htm Edgar Link pending
alt-20230930x10q002.jpg Edgar Link pending
alt-20230930xex31d1.htm Edgar Link pending
alt-20230930xex31d2.htm Edgar Link pending
alt-20230930xex32d1.htm Edgar Link pending
alt-20230930xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
alt-20230930_def.xml Edgar Link unprocessable
alt-20230930_lab.xml Edgar Link unprocessable
alt-20230930_pre.xml Edgar Link unprocessable
alt-20230930x10q_htm.xml Edgar Link completed
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
alt-20230930_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable